Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent furosemide timing strategies in CABG
IRCT20260718070231N1Phase 2Recruiting
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of furosemide in acute kidney failure (AKF) and coronary arteriosclerosis (4 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Serum creatinine, Blood urea nitrogen and 3 more. Started Sep 2026; status: recruiting.
02
Drugs
furosemide
03
Conditions
acute kidney failure (AKF)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20260718070231N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260718070231N1.